Merck & Company, Inc. (NYSE:MRK) had its price target lowered by analysts at Deutsche Bank AG from $62.00 to $59.00 in a research note issued to investors on Friday. The firm currently has a “hold” rating on the stock. Deutsche Bank AG’s target price points to a potential upside of 8.52% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the company. Jefferies Group LLC reissued a “sell” rating and issued a $52.00 price target on shares of Merck & in a research note on Sunday, August 20th. BMO Capital Markets reissued a “buy” rating and issued a $72.00 price target on shares of Merck & in a research note on Friday, September 8th. Credit Suisse Group decreased their price target on Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a research note on Wednesday, August 30th. SunTrust Banks, Inc. cut Merck & from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Finally, Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. Merck & currently has an average rating of “Hold” and an average target price of $66.44.

Shares of Merck & (MRK) opened at $54.37 on Friday. The firm has a market capitalization of $148,127.64, a price-to-earnings ratio of 13.98, a PEG ratio of 2.34 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. Merck & has a 1 year low of $53.63 and a 1 year high of $66.80.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business had revenue of $10.33 billion during the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the prior year, the company earned $1.07 EPS. Merck &’s revenue for the quarter was down 2.0% on a year-over-year basis. sell-side analysts anticipate that Merck & will post 3.95 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/merck-company-inc-mrk-price-target-lowered-to-59-00-at-deutsche-bank-ag/1723463.html.

In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.25% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Chicago Partners Investment Group LLC lifted its holdings in Merck & by 1,394.7% during the third quarter. Chicago Partners Investment Group LLC now owns 5,366 shares of the company’s stock worth $344,000 after acquiring an additional 5,007 shares during the period. Institutional & Family Asset Management LLC increased its position in Merck & by 4.0% in the third quarter. Institutional & Family Asset Management LLC now owns 55,845 shares of the company’s stock worth $3,576,000 after buying an additional 2,152 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Merck & in the third quarter worth $4,922,000. Public Employees Retirement System of Ohio increased its position in Merck & by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 1,916,777 shares of the company’s stock worth $122,731,000 after buying an additional 6,997 shares during the last quarter. Finally, Coastline Trust Co increased its position in Merck & by 5.5% in the third quarter. Coastline Trust Co now owns 60,579 shares of the company’s stock worth $3,878,000 after buying an additional 3,180 shares during the last quarter. Institutional investors own 72.98% of the company’s stock.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.